中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2015年
10期
1603-1607
,共5页
潘耀柱%白海%王存邦%葸瑞%张茜%王晓靖
潘耀柱%白海%王存邦%葸瑞%張茜%王曉靖
반요주%백해%왕존방%사서%장천%왕효정
干细胞%移植%外周T细胞淋巴瘤%自体造血干细胞移植%疗效%预处理%第1次完全缓解%造血重建%总生存率%不良反应
榦細胞%移植%外週T細胞淋巴瘤%自體造血榦細胞移植%療效%預處理%第1次完全緩解%造血重建%總生存率%不良反應
간세포%이식%외주T세포림파류%자체조혈간세포이식%료효%예처리%제1차완전완해%조혈중건%총생존솔%불량반응
Hematopoietic Stem Cel Transplantation%Lymphoma,T-Cel,Peripheral%Transplantation Conditioning
背景:外周T细胞淋巴瘤亚洲地区发病率高,具有侵袭性,预后普遍较差,目前尚无标准治疗策略。目的:评价自体造血干细胞移植治疗外周T细胞淋巴瘤的疗效及毒副反应。方法:回顾性分析2003年3月至2014年4月行自体造血干细胞移植治疗外周T细胞淋巴瘤35例,包括结外NK/T细胞淋巴瘤鼻型22例,血管免疫母细胞T细胞淋巴瘤1例,外周T细胞淋巴瘤(非特殊型)8例,间变性大T细胞淋巴瘤 ALK(+)3例,ALK(-)1例;所有病例均按WHO 2001年和WHO 2008年分类进行病理分型,均采用VAEMMC+全射照射预处理方案。结果与结论:随访中位时间54个月(9-120个月),28例患者(80%)存活,其中无病存活25例(71%),8例(23%)复发,其中7例死亡,1例尚在治疗中。近期毒性主要为骨髓造血受抑,无明显远期并发症。结果表明自体造血干细胞移植治疗外周T细胞淋巴瘤安全有效,早期(第1次完全缓解)行移植疗效佳。
揹景:外週T細胞淋巴瘤亞洲地區髮病率高,具有侵襲性,預後普遍較差,目前尚無標準治療策略。目的:評價自體造血榦細胞移植治療外週T細胞淋巴瘤的療效及毒副反應。方法:迴顧性分析2003年3月至2014年4月行自體造血榦細胞移植治療外週T細胞淋巴瘤35例,包括結外NK/T細胞淋巴瘤鼻型22例,血管免疫母細胞T細胞淋巴瘤1例,外週T細胞淋巴瘤(非特殊型)8例,間變性大T細胞淋巴瘤 ALK(+)3例,ALK(-)1例;所有病例均按WHO 2001年和WHO 2008年分類進行病理分型,均採用VAEMMC+全射照射預處理方案。結果與結論:隨訪中位時間54箇月(9-120箇月),28例患者(80%)存活,其中無病存活25例(71%),8例(23%)複髮,其中7例死亡,1例尚在治療中。近期毒性主要為骨髓造血受抑,無明顯遠期併髮癥。結果錶明自體造血榦細胞移植治療外週T細胞淋巴瘤安全有效,早期(第1次完全緩解)行移植療效佳。
배경:외주T세포림파류아주지구발병솔고,구유침습성,예후보편교차,목전상무표준치료책략。목적:평개자체조혈간세포이식치료외주T세포림파류적료효급독부반응。방법:회고성분석2003년3월지2014년4월행자체조혈간세포이식치료외주T세포림파류35례,포괄결외NK/T세포림파류비형22례,혈관면역모세포T세포림파류1례,외주T세포림파류(비특수형)8례,간변성대T세포림파류 ALK(+)3례,ALK(-)1례;소유병례균안WHO 2001년화WHO 2008년분류진행병리분형,균채용VAEMMC+전사조사예처리방안。결과여결론:수방중위시간54개월(9-120개월),28례환자(80%)존활,기중무병존활25례(71%),8례(23%)복발,기중7례사망,1례상재치료중。근기독성주요위골수조혈수억,무명현원기병발증。결과표명자체조혈간세포이식치료외주T세포림파류안전유효,조기(제1차완전완해)행이식료효가。
BACKGROUND:The incidence rate of peripheral T cel lymphoma is high in Asia, and peripheral T cel lymphoma is aggressive with generaly poor prognosis. However, there is no standard treatment strategy. OBJECTIVE:To retrospectively analyze the therapeutic effect of autologous hematopoietic stem cel transplantation on peripheral T cel lymphoma as wel as relevant toxic and side effects. METHODS:A retrospective review was conducted in 35 patients with peripheral T cel lymphoma who underwent autologous hematopoietic stem cel transplantation from March 2003 to April 2014, including 22 cases of extranodal NK/T-cel lymphoma (nasal type), 1 case of angioimmunoblastic T-cel lymphoma, 8 cases of peripheral T cel lymphoma (non-specific), 3 cases of ALK-positive anaplastic large cel lymphoma, and 1 case of ALK-negative anaplastic large cel lymphoma. Al of 35 patients were classified pathologicaly according to WHO pathological type in 2001 and 2008, and received the high-dose chemotherapy with vincristine, cytarabine, etoposide, mitoxantrone, semustine, cyclophosphamide, and total body irradiation. RESULTS AND CONCLUSION: After a median folow-up of 54 (9-120) months, the probabilities of overal survival and disease-free survival after transplantation were 80% (n=28) and 71% (n=25), respectively. Eight cases (23%) relapsed after transplantation, seven of which died. It was safe with mild and moderate transplantation related side-effects on opportunistic infections, oral cavity mucosa and bladder responses and so on, and there were no severe, life-threatening late complications. Autologous hematopoietic stem cel transplantation may be an effective and safe treatment for peripheral T cel lymphoma, and there is a better benefit in peripheral T cel lymphoma patients with first complete remission.